What's Happening?
Researchers have reported that a new experimental pill, enlicitide, significantly reduces artery-clogging cholesterol in patients at high risk of heart attacks, even those already on statins. The pill, which is still awaiting FDA approval, offers a potential
alternative to injected medicines currently used to lower LDL cholesterol. In a study involving over 2,900 high-risk patients, those taking enlicitide saw their LDL cholesterol levels drop by up to 60% over six months. The study, funded by Merck, suggests that enlicitide could provide a more convenient option for millions of people who struggle to manage their cholesterol levels with existing treatments.
Why It's Important?
Heart disease remains the leading cause of death in the U.S., with high LDL cholesterol being a major risk factor. Current treatments, including statins and PCSK9 inhibitors, are effective but have limitations, such as the need for injections and complex prescriptions. Enlicitide could simplify treatment regimens, making it easier for patients to adhere to their medication plans. This development could potentially reduce the incidence of heart attacks and strokes, improving public health outcomes and reducing healthcare costs associated with cardiovascular diseases.
What's Next?
The FDA has included enlicitide in a program for ultra-fast reviews, indicating a potential expedited approval process. Merck is conducting a larger study involving over 14,000 patients to determine if the cholesterol reduction observed with enlicitide translates into fewer heart attacks and strokes. If successful, enlicitide could become a widely used treatment, changing the landscape of cholesterol management and offering a new option for patients who are unable to achieve desired cholesterol levels with current medications.
